- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New GSK Chief Will Be "Most Powerful" UK Female CEO
Emma Walmsley will succeed Andrew Witty next year and become the seventh female chief executive in the FTSE 100.
GSK today announced that Emma Walmsley, currently Chief Executive Officer of GSK’s Consumer Healthcare division, has been appointed GSK CEO Designate and will succeed Andrew Witty when he retires on March 31, 2017. Walmlsey will join the GSK Board of Directors from January 1, 2017. She has been a member of GSK’s Corporate Executive Team since 2011, joining the company in 2010 from L’Oreal where she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China. The appointment sees Walmsley, 47, become the seventh female chief executive in the FTSE 100, The Telegraph reported, and makes her "arguably the most powerful female boss in the index".
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
